AQR Capital Management
ODT

AQR Capital Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

AQR Capital Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,430
Closed -$399K – 2306
2020
Q2 		$399K Buy
9,430
+88
+0.9% +$2.85K ﹤0.01% 1822
2020
Q1 		$258K Buy
9,342
+433
+5% +$12.6K ﹤0.01% 1812
2019
Q4 		$289K Buy
+8,909
New +$276K ﹤0.01% 1918

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

AQR Capital Management's ODT Position: Q3 2020 in Review

AQR Capital Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q3 2020, closing a stake of 9,430 shares — an estimated $399K sold.

AQR Capital Management first reported a position in ODT in Q4 2019 and held it in 3 quarters. The position peaked at $399K in Q2 2020. 89 funds tracked by Wall St. Rank hold ODT as of Q3 2020.

  • AQR Capital Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • AQR Capital Management sold 9,430 Odonate Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $399K.
  • AQR Capital Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
  • AQR Capital Management's Odonate Therapeutics, Inc. Common Stock position peaked at $399K in Q2 2020.
  • 89 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q3 2020.

Based on AQR Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.